Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 26 of 32 for:    FLUORIDE ION AND NITRATE ION

Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02918617
Recruitment Status : Completed
First Posted : September 29, 2016
Results First Posted : November 16, 2018
Last Update Posted : November 16, 2018
Sponsor:
Collaborator:
Sangi Co., Ltd.
Information provided by (Responsible Party):
Bennett Amaechi, The University of Texas Health Science Center at San Antonio

Brief Summary:
This study will investigate the effectiveness of nanohydroxyapatite (nano-HAP)-containing toothpastes and cream to relieve dentin hypersensitivity, comparing it with those of a commercial desensitizing dentifrice containing calcium sodium phosphosilicate (Novamin® technology) and a standard fluoride dentifrice containing 1,500 ppm fluoride as sodium monofluorophosphate (MFP).

Condition or disease Intervention/treatment Phase
Dentin Sensitivity Drug: Control toothpaste containing Novamin® technology Drug: Control toothpaste containing 1500 ppm fluoride as MFP Drug: Test toothpaste with nano-HAP (high concentration) Drug: Test toothpaste with nano-HAP (low concentration) Drug: Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3 Drug: Control toothpaste without nano-HAP Drug: Test toothpaste with nano-HAP (medium concentration) Drug: Test cream with nano-HAP (higher concentration) Drug: Control cream without nano-HAP Phase 2

Detailed Description:
This is a double-blind, randomized, controlled, parallel group, outpatient clinical trial, involving a total of 270 patients diagnosed with dentin hypersensitivity, who will be randomly assigned to nine treatment groups of 30 patients each. Males or females of age 18 to 80 years will be enrolled. The nine groups will be randomly assigned to use one of the nine test products: (1) toothpaste containing nano-HAP (high concentration); (2) toothpaste containing nano-HAP (low concentration); (3) toothpaste containing nano-HAP and potassium nitrate (KNO3); (4) toothpaste containing NovaMin; (5) standard fluoride toothpaste with 1500 ppm MFP; (6) toothpaste containing nano-HAP (medium concentration); (7) placebo toothpaste; (8) cream containing nano-HAP; (9) placebo cream. Subjects will be instructed to use the study toothpaste as their sole oral hygiene product for the 8 weeks treatment duration while the cream will be applied with a retainer tray for 5 minutes before bed at night. For those using toothpastes, subjects will be instructed to brush their teeth twice daily for 2 minutes, morning and last thing before bed, applying on each occasion a one-inch strip of their assigned toothpaste on a wetted commercially available soft-bristled toothbrush. Dentin hypersensitivity examination, which will include air blast sensitivity and cold thermal sensitivity combined with visual analog scale and Dental Pain Scale, will be conducted at baseline, 2, 4, 6, and 8 weeks. Subjects will be screened for adverse effects on every visit, and all observed adverse events will be recorded when they occur.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 203 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream
Actual Study Start Date : May 2015
Actual Primary Completion Date : September 2016
Actual Study Completion Date : September 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy

Arm Intervention/treatment
Active Comparator: Control toothpaste containing Novamin® technology
Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
Drug: Control toothpaste containing Novamin® technology
Placebo Comparator: Control toothpaste containing 1500 ppm fluoride as MFP
Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
Drug: Control toothpaste containing 1500 ppm fluoride as MFP
Experimental: Test toothpaste with nano-HAP (high concentration)
Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
Drug: Test toothpaste with nano-HAP (high concentration)
Experimental: Test toothpaste with nano-HAP (low concentration)
Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
Drug: Test toothpaste with nano-HAP (low concentration)
Experimental: Test toothpaste with nano-HAP and potassium nitrate (KNO3)
Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
Drug: Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3
Placebo Comparator: Control toothpaste without nano-HAP
Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
Drug: Control toothpaste without nano-HAP
Experimental: Test toothpaste with nano-HAP (medium concentration)
Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
Drug: Test toothpaste with nano-HAP (medium concentration)
Experimental: Test cream with nano-HAP (higher concentration)
Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
Drug: Test cream with nano-HAP (higher concentration)
Placebo Comparator: Control cream without nano-HAP
Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
Drug: Control cream without nano-HAP



Primary Outcome Measures :
  1. Percentage Change From Baseline in VAS (Visual Analog Scale) With Air Stimulation [ Time Frame: Baseline to 8 weeks ]
    Patient's response to an air stimulus is recorded on a Visual Analog Scale of 0-100 with 0 representing no pain and 100 representing the worst possible pain.

  2. Percentage Change From Baseline in VAS (Visual Analog Scale) With Cold Stimulation [ Time Frame: Baseline to 8 weeks ]
    Patient's response to cold stimulus is recorded on a Visual Analog Scale of 0-100 with 0 signifying no pain and 100 signifying the worst possible pain

  3. Percentage Change From Baseline in DPS (Dental Pain Scale) With Air Stimulation [ Time Frame: Baseline to 8 weeks ]
    Patient's response to an air stimulus is recorded on a Dental Pain Scale (none[1]-mild[2]-moderate[3]-severe[4]).

  4. Percentage Change From Baseline in DPS (Dental Pain Scale) With Cold Stimulation [ Time Frame: Baseline to 8 weeks ]
    Patient's response to an cold stimulus is recorded on a Dental Pain Scale (none[1]-mild[2]-moderate[3]-severe[4]).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must be between the ages of 18 and 80, inclusive
  • Must be in good general health based on medical history and oral soft and hard tissue examinations
  • Must be willing and able to provide informed consent
  • Must be able to read and comprehend study materials
  • Must have access to a phone for regular study contact
  • Must be willing to use the assigned products according to instructions, and be availability for appointments.
  • Must have been diagnosed of having dentin hypersensitivity by a dentist, with at least one sensitive tooth with demonstrated cervical erosion/abrasion or gingival recession
  • As a final entrance criteria, the sensitive tooth must respond to:

    • air sensitivity, with Schiff score >1, assessed by use of a one-second blast of air.
    • thermal sensitivity, assessed with frozen cotton pellet, with a pain rating of at least moderate pain on the Dental Pain Scale (DPS) and a score between 30 and 80 mm on a 100 mm scale on the Visual Analog Scale (VAS).

Exclusion Criteria:

  • Subjects who answer YES to any of the following questions will not be enrolled into the study:

    • Any history of significant adverse effects following use of oral hygiene products such as toothpastes and mouthwashes?
    • Does the subject have any physical limitations or restrictions that might preclude use of normal oral hygiene procedures (i.e., toothbrushing, mouthrinsing, etc.)?
    • The sensitive tooth is associated with concomitant oral pain due to any other condition such as: soft-tissue lesions or toothache from other dental conditions like dental caries, etc?
    • Has the subject ever reported allergy to drugs or chemicals used in the trial?
    • The sensitive tooth is associated with a periodontal abscess as diagnosed from an X-ray or clinical examination of the tooth?
    • Will the subject receive dental treatment which may affect their participation (i.e. oral prophylaxis)?
    • The sensitive tooth is associated with mobility > 1?
    • Did the subject participate in a dental clinical trial involving oral care products within the past 30 days?
    • Is the subject pregnant, nursing or planning to become pregnant during the course of the study (self-reported)?
    • Does the subject have other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial result and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial?
    • Does the subject have significant oral soft tissue pathology, based on the dentist's visual examination and at the discretion of the investigator?
    • The sensitive tooth is associated with gum pain from gingivitis, occlusal trauma, thermal or chemical burns?
    • Patients having pain from periodontal related causes but not dentin hypersensitivity?
    • Previous professional desensitizing treatment?
    • Subject use of over-the-counter desensitizing products within the previous 3 months?
    • Subjects using medication which could interfere with the perception of pain?
    • Eating disorders or conditions associated with vomiting?
    • Systemic conditions that are etiologic or predisposing to dentinal hypersensitivity?
    • Excessive dietary or environmental exposure to acids?
    • The sensitive tooth was restored in the preceding 3 months?
    • The sensitive tooth is an abutment tooth for fixed or removable prostheses?
    • The sensitive tooth has extensive restorations or restoration extending into the test area?
    • Patients below 18 years or above 80 years of age?

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02918617


Locations
Layout table for location information
United States, Texas
School of Dentistry, University of Texas Health Science Center
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
Sangi Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Bennett T Amaechi, BDS, MS, PhD University of Texas Health Science Center San Antonio

Publications:
Layout table for additonal information
Responsible Party: Bennett Amaechi, Professor, Department of Comprehensive Dentistry, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT02918617     History of Changes
Other Study ID Numbers: HSC20150221H
First Posted: September 29, 2016    Key Record Dates
Results First Posted: November 16, 2018
Last Update Posted: November 16, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Bennett Amaechi, The University of Texas Health Science Center at San Antonio:
dentin hypersensitivity
nanohydroxyapatite
calcium sodium phosphosilicate
toothpaste
tooth cream
Additional relevant MeSH terms:
Layout table for MeSH terms
Dentin Sensitivity
Hypersensitivity
Immune System Diseases
Tooth Diseases
Stomatognathic Diseases
Fluorides
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs